Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Arcus Biosciences (NYSE: RCUS), a biopharmaceutical company focused on developing cancer therapies, announced participation in two upcoming investor conferences. The first is the SVB Leerink 11th Annual Global Healthcare Conference, scheduled for February 16, 2022, at 1:20 p.m. PT, and the second is the Barclay’s Global Healthcare Conference on March 17, 2022, at 1:35 p.m. ET. Live audio webcasts will be available on the Arcus Biosciences website, and replays will be accessible for two weeks after the events.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to six new employees, totaling 64,050 shares at an exercise price of $30.30, equivalent to the closing price on February 8, 2022. Additionally, 2,025 restricted stock units were awarded. These grants were made under the Company’s 2020 Inducement Plan, approved in January 2020, complying with NYSE regulations. Founded in 2015, Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted options to purchase 38,850 shares and restricted stock units for 925 shares to six new employees. The exercise price is set at $31.75, equivalent to the closing price on January 24, 2022. The equity awards comply with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus Biosciences is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to two new employees totaling 41,800 shares at an exercise price of $37.56, the closing price on January 10, 2022. This issuance is in accordance with the Company’s 2020 Inducement Plan, approved under NYSE rules. Founded in 2015, Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies targeting various cancer pathways.
Arcus Biosciences (NYSE:RCUS) updates on its clinical programs, detailing six molecules targeting cancer pathways. In 2022, it anticipates multiple data presentations, including results from ARC-7 and ARC-8 studies. Despite initial data from the ARC-4 study showing no significant differentiation in clinical activity for etrumadenant, ongoing efforts continue in other studies. Arcus expects its cash position to nearly double to $1.4 billion following option payments from Gilead, enhancing funding for future clinical trials.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to four new employees totaling 23,400 shares at an exercise price of $44.59, the closing price on December 23, 2021. This grant is part of the Company’s 2020 Inducement Plan, approved by the Board of Directors in January 2020. The company focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies targeting various biological pathways.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) confirmed the closure of Gilead's option exercises on three of Arcus’ clinical-stage programs, including domvanalimab, AB308, etrumadenant, and quemliclustat, as of November 17, 2021. This transaction, following the expiration of antitrust waiting periods, entitles Arcus to receive $725 million from Gilead. Future collaboration includes co-development and profit-sharing in the U.S., along with tiered royalties on international sales. The collaboration supports advancements in cancer treatment through innovative drug candidates.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced the closing of Gilead's option exercises for three clinical-stage programs in Arcus's portfolio, including anti-TIGIT molecules and other candidates. This agreement results in option payments of $725 million from Gilead to Arcus, expected in early Q1 2022. Under the collaboration, Gilead and Arcus will co-develop the programs and share costs, with Gilead holding exclusive commercialization rights outside the U.S. The transaction followed the expiration of the Hart-Scott-Rodino waiting period.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options to eight new employees, allowing them to purchase a total of 83,400 shares at $44.17 each, reflecting the closing price on December 8, 2021. This issuance is part of the 2020 Inducement Plan approved in January 2020 under the NYSE rule for inducements. Arcus focuses on developing innovative cancer therapies and has initiated six investigational medicines targeting key biological pathways.
Arcus Biosciences (NYSE:RCUS) and Taiho Pharmaceutical announced the exercise of Taiho's option for the anti-TIGIT antibodies, domvanalimab and AB308, in Japan and parts of Asia. This follows a prior agreement from September 2017. Taiho will make an upfront payment and additional milestone payments. Domvanalimab is in Phase 2 and Phase 3 trials for non-small cell lung cancer, while AB308 is in a Phase 1b trial for various malignancies. The collaboration aims to enhance the development and commercialization of these therapies.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?
What is the mission of Arcus Biosciences?
